Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen
Solna, 23 June 2022. The Board of Directors of Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”) has resolved on a directed issue of 3,896,885 shares to Östersjöstiftelsen (ÖSS) following a request for conversion in accordance with convertible loan agreement between Asarina Pharma and ÖSS entered into in May 2021.On 31 May 2021, Asarina Pharma announced by press release that the Company had signed a convertible loan agreement with ÖSS (the “Loan Agreement”). ÖSS has now, in accordance with the Loan Agreement, requested that Asarina Pharma repay the outstanding loan amount plus